Adverse events 5% in SUSTAIN 5 8,10 AEs occurring in 5% of participants treated with Ozempic injection in SUSTAIN 5 Incidence of severe hypoglycemia was 1.5% across all placebo-controlled trials 1 Incidence of severe hypoglycemia or blood glucose-confirmed hypoglycemia (% of patients) was 8,10 : 8.3% with Ozempic injection 0.5 mg + basal insulin MET 10.7% with Ozempic injection 1 mg + basal insulin MET 5.3% with placebo + basal insulin MET Patients receiving Ozempic injection in combination with an insulin secretagogue (eg, sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia 1 Adverse events 5% in SUSTAIN FORTE 4 AEs occurring in 5% of patients receiving Ozempic injection 1 mg and 2 mg in SUSTAIN FORTE In placebo-controlled trials, the most common adverse reactions reported in 5% of patients treated with Ozempic injection are nausea, vomiting, diarrhea, abdominal pain, and constipation 1 No new safety signals were identified
Hydration becomes critical because reduced food intake often means lower electrolyte intake, and sweat losses during exercise compound this
Finally, a Weight Loss Treatment That Works for You Semaglutide is a medical weight loss drug designed to help people lose weight by reducing hunger and appetite
Semaglutide slows gastric emptyingthe rate at which food moves from your stomach into your small intestinewhich contributes to increased satiety and reduced appetite, though this effect may diminish over time with continued treatment
Techniques such as yoga, meditation, or simple breathing exercises can reduce stress and help your digestive system function more smoothly
Wang L, Chen T, Wang H, Wu X, Cao Q, Wen K, et al
